- Increases glucagon secretion.
- Mimics incretin hormones, stimulating glucose-dependent insulin release, suppressing glucagon, and slowing gastric emptying.
- Increases glucose absorption.
- Decreases insulin sensitivity.
200. A patient with Type 2 Diabetes Mellitus is prescribed a GLP-1 receptor agonist (e.g., liraglutide). From a medicinal perspective, what is the technical pathophysiological mechanism of GLP-1 agonists?
Facebook
WhatsApp
